For patients undergoing stereotactic body radiotherapy (SBRT) for prostate cancer, the acute genitourinary (GU) toxicity rate associated with the procedure was 19 percent lower with magnetic resonance imaging (MRI) guidance in comparison to computed tomography (CT) guidance, according to new research presented recently at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Emerging research suggests that magnetic resonance imaging (MRI) guidance is more advantageous than computed tomography (CT) guidance in reducing genitourinary (GU) and gastrointestinal (GI) side effects of stereotactic body radiotherapy (SBRT).
Reporting on findings from a phase III randomized trial (MIRAGE) at the recent American Society for Radiation Oncology (ASTRO) Annual Meeting, researchers reported a 43.4 percent rate of acute grade >2 GU toxicity for CT-guided SBRT in comparison to a 24.4 percent rate of acute grade >2 GU toxicity for MRI-guided SBRT with the MRIdian MRI system (ViewRay). The researchers added that a subsequent multivariable analysis, accounting for differences in prostate size, baseline urinary symptoms and use of a hydrogel spacer, revealed a 60 percent reduction in the risk of grade >2 GU toxicity with MRI guidance.
In the study, which involved 156 patients, the authors indicated that none of the patients in the MRI group had acute grade >2 GI toxicity in comparison to a 10.5 percent toxicity rate in the CT group.
In regard to patient-reported outcomes with prostate SBRT, the incidence of increased urinary symptoms measured by the International Prostate Symptom Score was 12.6 percent lower in the MRI guidance group, according to the study. The researchers also noted that half of the patients in the CT guidance group reported a decrease in bowel-related quality of life in comparison to 25 percent of those who had MRI-guided SBRT.
With these study results, Amar Kishan, M.D, a co-author of the study, said he and his colleagues at the University of California, Los Angeles (UCLA) have shifted to nearly “exclusive” use of MRI-guided prostate SBRT after offering CT-guided prostate SBRT since 2010.
“A major consideration with prostate SBRT is the margin of normal tissue around the target that is exposed to high-dose radiation. The highly positive final results of our phase III MIRAGE trial show that when MRI guidance is used to shrink that margin, there are significant improvements in both physician-scored and patient-reported toxicity in terms of urinary and bowel side effects,” noted Dr. Kishan, an associate professor and chief of the Genitourinary Oncology Service at UCLA.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
July 22nd 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.